Search results
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Zacks via Yahoo Finance· 9 hours agoBiogen BIIB announced that the European Commission (EC) has granted marketing approval to Qalsody...
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Benzinga via Yahoo Finance· 7 hours agoOn Thursday, the European Commission granted marketing authorization under exceptional circumstances...
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors
Guru Focus· 8 hours agoLong-established in the Drug Manufacturers industry, Biogen Inc (BIIB, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, ...
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
Simply Wall St. via Yahoo Finance· 4 days agoIt is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock...
... Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen...
Morningstar· 1 day agoLaw Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB
... Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit...
Morningstar· 1 day agoPomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain officers. The class action, filed ...
European Commission grants marketing approval to Biogen's ALS drug
Reuters· 1 day ago, opens new tab said on Thursday that the European Commission has granted marketing authorization...
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with...
Benzinga· 6 days agoRudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. BIIB securities between February 3, 2022 and February 13, 2024, both dates inclusive (the "Class Period ...
RBC maintains $317 price target on Biogen stock, cites Skyclarys importance By Investing.com
Investing.com· 2 days agoOn Wednesday, RBC (TSX:RY) Capital maintained its Outperform rating on Biogen (NASDAQ:BIIB) shares...
BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after...
Morningstar· 2 days agoNEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities ...